Related Experiment Video

Updated: Sep 7, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.4K

Cardiac biomarkers and mortality in COVID-19 infection: A review

Angelica Cersosimo1, Giuliana Cimino2, Ludovica Amore3

  • 1Department of Medical and Surgical Specialties, Institute of Cardiology, University of Brescia. angelica.cersosimo@gmail.com.

Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace
|June 23, 2022
PubMed

Insights

Elevated cardiac biomarkers like troponins indicate acute myocardial damage in hospitalized COVID-19 patients. Monitoring these biomarkers is crucial for predicting outcomes and managing cardiovascular risk.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Biomarkers

Background:

  • Hospitalized patients with moderate to severe COVID-19 frequently experience acute myocardial damage.
  • This damage is evidenced by elevated cardiac biomarkers, including N-terminal pro-B-type natriuretic peptide (NT-pro-BNP), creatine kinase-myocardial band (CK-MB), and troponins.
  • Higher mortality rates correlate with increasing biomarker levels and pre-existing cardiovascular disease.

Purpose of the Study:

  • To review cardiovascular prognostic factors in COVID-19 patients.
  • To analyze cardiac biomarkers for early identification of severe cases.
  • To optimize patient outcomes through prognostic assessment.

Main Methods:

  • Review of meta-analyses and studies on COVID-19 and cardiac biomarkers.
  • Analysis of data linking cardiac biomarker levels to patient outcomes.
  • Evaluation of prognostic significance of biomarkers at admission, during hospitalization, and upon clinical deterioration.

Main Results:

  • Acute myocardial damage is a significant complication in hospitalized COVID-19 patients.
  • Cardiac biomarkers serve as critical prognostic indicators.
  • Cardiovascular disease history exacerbates mortality risk in conjunction with elevated biomarkers.

Conclusions:

  • Biomarker monitoring is essential for risk stratification in COVID-19 patients.
  • Early identification of elevated cardiac biomarkers aids in managing severe cases.
  • Prognostic assessment using cardiac biomarkers can improve patient outcomes.

More Related Videos

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

11.7K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.2K

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
328
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
213
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
21
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
43
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
20
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15